136 related articles for article (PubMed ID: 12817992)
21. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
22. Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice.
Kwan H; Pecenka V; Tsukamoto A; Parslow TG; Guzman R; Lin TP; Muller WJ; Lee FS; Leder P; Varmus HE
Mol Cell Biol; 1992 Jan; 12(1):147-54. PubMed ID: 1530875
[TBL] [Abstract][Full Text] [Related]
23. Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development.
Jolicoeur P; Bouchard L; Guimond A; Ste-Marie M; Hanna Z; Dievart A
Biochem Soc Symp; 1998; 63():159-65. PubMed ID: 9513720
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid.
Szeto W; Jiang W; Tice DA; Rubinfeld B; Hollingshead PG; Fong SE; Dugger DL; Pham T; Yansura DG; Wong TA; Grimaldi JC; Corpuz RT; Singh JS; Frantz GD; Devaux B; Crowley CW; Schwall RH; Eberhard DA; Rastelli L; Polakis P; Pennica D
Cancer Res; 2001 May; 61(10):4197-205. PubMed ID: 11358845
[TBL] [Abstract][Full Text] [Related]
25. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors.
Morrison BW; Leder P
Oncogene; 1994 Dec; 9(12):3417-26. PubMed ID: 7970700
[TBL] [Abstract][Full Text] [Related]
26. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
[TBL] [Abstract][Full Text] [Related]
27. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer.
Li Y; Hively WP; Varmus HE
Oncogene; 2000 Feb; 19(8):1002-9. PubMed ID: 10713683
[TBL] [Abstract][Full Text] [Related]
28. Induction of epithelial abnormalities that resemble human breast lesions by the expression of the neu/erbB-2 oncogene in reconstituted mouse mammary gland.
Bradbury JM; Arno J; Edwards PA
Oncogene; 1993 Jun; 8(6):1551-8. PubMed ID: 8099220
[TBL] [Abstract][Full Text] [Related]
29. The transcriptional repressor Snail promotes mammary tumor recurrence.
Moody SE; Perez D; Pan TC; Sarkisian CJ; Portocarrero CP; Sterner CJ; Notorfrancesco KL; Cardiff RD; Chodosh LA
Cancer Cell; 2005 Sep; 8(3):197-209. PubMed ID: 16169465
[TBL] [Abstract][Full Text] [Related]
30. Clonal variations among multiple primary mammary tumors and within a tumor of individual mice: insertion mutations of int oncogenes.
Sarkar NH
Virology; 1995 Oct; 212(2):490-9. PubMed ID: 7571419
[TBL] [Abstract][Full Text] [Related]
31. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
32. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.
Koman IE; Commane M; Paszkiewicz G; Hoonjan B; Pal S; Safina A; Toshkov I; Purmal AA; Wang D; Liu S; Morrison C; Gudkov AV; Gurova KV
Cancer Prev Res (Phila); 2012 Aug; 5(8):1025-35. PubMed ID: 22689915
[TBL] [Abstract][Full Text] [Related]
33. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
34. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability.
Donehower LA; Godley LA; Aldaz CM; Pyle R; Shi YP; Pinkel D; Gray J; Bradley A; Medina D; Varmus HE
Genes Dev; 1995 Apr; 9(7):882-95. PubMed ID: 7705663
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
36. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY
Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107
[TBL] [Abstract][Full Text] [Related]
37. Amplification and proviral activation of several Wnt genes during progression and clonal variation of mouse mammary tumors.
Roelink H; Wagenaar E; Nusse R
Oncogene; 1992 Mar; 7(3):487-92. PubMed ID: 1549363
[TBL] [Abstract][Full Text] [Related]
38. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.
Theodorou V; Kimm MA; Boer M; Wessels L; Theelen W; Jonkers J; Hilkens J
Nat Genet; 2007 Jun; 39(6):759-69. PubMed ID: 17468756
[TBL] [Abstract][Full Text] [Related]
39. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development.
Jerry DJ; Kittrell FS; Kuperwasser C; Laucirica R; Dickinson ES; Bonilla PJ; Butel JS; Medina D
Oncogene; 2000 Feb; 19(8):1052-8. PubMed ID: 10713689
[TBL] [Abstract][Full Text] [Related]
40. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells.
Howe LR; Subbaramaiah K; Chung WJ; Dannenberg AJ; Brown AM
Cancer Res; 1999 Apr; 59(7):1572-7. PubMed ID: 10197631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]